Psychedelic retail stores illegally selling psilocybin, DMT and related substances have proliferated in Canada, with close to 60 brick-and-mortar shops documented in 2023. This echoes the pre-legalization and regulation cannabis landscape. Public responses have remained inconsistent, oscillating between de facto tolerance and enforcement of the law, raising ...
Interest in psychedelic-assisted therapy (PAT) is surging across research and medical communities, prompting the discussion of policy shifts that reflect growing openness to implementing psychedelics in clinical practice. State-level psychedelic reform in the United States has accelerated since 2019, with legalization projected to reach most states within th...
This article corrects an idea in psychedelic science and culture that the ancient Eleusynian Mysteries used psychedelics, as claimed by Carl Ruck and co-authors in (1978), revitalized by Brian Muraresku's (2020), and popularized by social media heavyweights such as Joe Rogan. It begins by exposing critical methodological flaws in the arguments, namely, a pat...
Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychedelics that are found in many plants but also excreted by some species of toads. The compounds are regulated differently around the world, and although used in traditional medicine, 20-century prohibition culture has slowed resea...
About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. We need treatments that work well, quickly, and ...
Background: Psilocybin has been granted breakthrough therapy status in the United States, speeding its advancement from research to clinical care. Due to the controversial nature of psilocybin, psychiatrists may not be fully prepared to incorporate it into clinical practice. The current study aimed to evaluate the opinions toward psilocybin among practicing ...
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both research and public health. This cross-sectional retrospective study examined 365 people who currently use psilocybin, analyzing differences in acute experiences, psychological outcomes, and substance co-use patterns....
Importance: Psilocybin use has surged in the US following decriminalization efforts and promising clinical trial results. Mirroring early cannabis legalization, public access and enthusiasm are outpacing regulatory oversight and scientific understanding, posing potential risks to public health. Objective: To review emerging evidence on the public health impl...
Clinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants. This updated review integrates recent developments, including data on lesser-studied compounds like DMT and 5-MeO-DMT, findings from large clinical trials, and evolving regulatory landscape...
This study examines the relationship between psilocybin reforms and usage patterns of prevalent psychedelics in the United States. Given decriminalization efforts in several cities and legalization in Oregon, the author analyzes drug use panel data from University of Michigan's Monitoring the Future project to assess changes in self-reported use of psilocybi...
BackgroundResearch into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines.ObjectiveThis study examines the legislations and regulatory fr...
Abstract Psychedelic drug use is experiencing a global resurgence, both in clinical research and community settings. This paper presents a comprehensive public health analysis of the naturalistic use of psychedelics-defined as use outside clinical or research environments. Drawing on a review of 104 peer-reviewed articles, this analysis evaluates the mental,...
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both research and public health. This cross-sectional study examined 365 current psilocybin users, analyzing differences in acute experiences, psychological outcomes, and substance co-use patterns. Participants were catego...
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both research and public health. This cross-sectional study examined 365 current psilocybin users, analyzing differences in acute experiences, psychological outcomes, and substance co-use patterns. Participants were catego...
Psychedelic medicine has existed for thousands of years as a traditional, sacred practice and is now in varying stages of legalization for clinical application in the United States. PsychedelicAssisted Therapy uses specific psychoactive substances to facilitate altered states of consciousness in which clients have access to unconscious material and there is ...
While the movement to liberalize psychedelics bears many parallels to that of cannabis, there are important differences that must be considered in development of regulatory policy. It is critical to avoid conflating debates about liberalization for therapeutic and recreational purposes. As with cannabis, this conflation has been driven by advocates of recrea...
OBJECTIVES: Promising studies show that psilocybin-assisted therapy relieves existential distress in patients with serious illnesses, a difficult condition to treat with current treatment options. There is growing interest in this therapy in palliative care. Canada recently amended its laws to allow physicians to request psilocybin for end-of-life distress. ...
